Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.47 |
| ▸ | YES1 | P07947 | 1/20 | 0.42 |
| ▸ | FGR | P09769 | 1/20 | 0.42 |
| ▸ | TEC | P42680 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | WEE1 | P30291 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725566 | 1.00 | BTK (0.47) | BTKYES1FGRTECBMX | |
| SCHEMBL1727460 | 0.91 | BTK (0.44) | BTKKCNH2MAP4K1 | |
| SCHEMBL1393209 | 0.91 | BTK (0.47) | BTK | |
| SCHEMBL14911790 | 0.88 | BTK (0.50) | BTK | |
| SCHEMBL31158062 | 0.88 | BTK (0.50) | BTK | |
| SCHEMBL1727627 | 0.83 | BTK (0.47) | BTK | |
| SCHEMBL10256147 | 0.82 | BTK (0.43) | BTKMAP4K1FLT3WEE1 | |
| SCHEMBL14913211 | 0.82 | BTK (0.39) | BTKYES1FGRTECBMX | |
| SCHEMBL29741894 | 0.82 | BTK (0.39) | BTKYES1FGRTECBMX | |
| SCHEMBL708026 | 0.80 | BTK (0.52) | BTKKCNH2MAP4K1FLT3WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | GENENTECH, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270747-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885YES1 388/4885FGR 697/4885 |
| US-20230279012-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS | PDXK, BTK, TYK2 | BTK 2/4885YES1 388/4885FGR 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.